| Author, year . | Time since first TAVR (months) . | Mean LVEF (%) . | Risk scores . | Peak gradient of degenerated THV (mean) . | Mean gradient of degenerated THV (mean) . | Pure stenosis of degenerated THV (n) . | Mixed stenosis and regurgitation of degenerated THV (n) . | Pure regurgitation of degenerated THV (n) . | Thrombosis of previous THV (n) . |
|---|---|---|---|---|---|---|---|---|---|
| Landes et al., 2020 [6] | 60 (range 18–72) | 51.1 ± 12 | NA | 57.2 ± 31.4 | 34.7 ± 19.9 | 51 (37%) | 45 (32.6%) | 41 (29.7%) | 14 (10.2%) |
| Tsuda et al., 2019 [7] | 46 ± 15.9 (range 24–60) | 61 (range 38–70) | STS score (%): 8.6 (range 5.8–22.5) | 43 | 33.3 | 3 | 1 | 2 | 0 |
| Abdel-Wahab et al., 2020 [8] | 84 | NA | NA | NA | NA | 1 | 0 | 0 | 0 |
| Eftychiou et al., 2018 [9] | 84 | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Hoffmann et al., 2012 [10] | 42 | 42 | EuroSCORE: 32% | NA | 45 | 1 | 0 | 0 | 0 |
| Jędrzejczyk et al., 2019 [11] | 72, 72 | 27 | NA | NA | NA | 0 | 0 | 2 | 0 |
| Yap et al., 2020 [12] | 72 | 35 | NA | NA | 40 | 1 | 0 | 0 | 0 |
| Long and Mahoney, 2018 [13] | 50 | 50 | NA | 141 | 80 | 1 | 0 | 0 | 0 |
| Lotfi et al., 2017 [14] | 12 | Impaired with LVAD | EuroSCORE: 24.36% | NA | NA | 0 | 0 | 1 | 0 |
| Nascimento et al., 2019 [15] | NA | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Toggweiler et al., 2018 [16] | 96 | NA | NA | NA | 26 | 0 | 0 | 1 | 0 |
| Yamashita et al., 2019 [17] | 47 | NA | STS score: 9.5% | 95 | 58 | NA | NA | NA | NA |
| Salaun et al., 2019 [18] | 62.4 ± 23 (range 36–96) | NA | NA | NA | 39.6 ± 13.8 | 3 | 1 | 1 | 0 |
| Total | 58.1 ± 23.4 (21 cases) | 41 ± 10.2% | – | 84 ± 43.8 | 44.5 ± 18.5 | 61/159 (38.4%) | 47/159 (29.5%) | 50/159 (31.4%) | 14/159 (8.8%) |
| Author, year . | Time since first TAVR (months) . | Mean LVEF (%) . | Risk scores . | Peak gradient of degenerated THV (mean) . | Mean gradient of degenerated THV (mean) . | Pure stenosis of degenerated THV (n) . | Mixed stenosis and regurgitation of degenerated THV (n) . | Pure regurgitation of degenerated THV (n) . | Thrombosis of previous THV (n) . |
|---|---|---|---|---|---|---|---|---|---|
| Landes et al., 2020 [6] | 60 (range 18–72) | 51.1 ± 12 | NA | 57.2 ± 31.4 | 34.7 ± 19.9 | 51 (37%) | 45 (32.6%) | 41 (29.7%) | 14 (10.2%) |
| Tsuda et al., 2019 [7] | 46 ± 15.9 (range 24–60) | 61 (range 38–70) | STS score (%): 8.6 (range 5.8–22.5) | 43 | 33.3 | 3 | 1 | 2 | 0 |
| Abdel-Wahab et al., 2020 [8] | 84 | NA | NA | NA | NA | 1 | 0 | 0 | 0 |
| Eftychiou et al., 2018 [9] | 84 | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Hoffmann et al., 2012 [10] | 42 | 42 | EuroSCORE: 32% | NA | 45 | 1 | 0 | 0 | 0 |
| Jędrzejczyk et al., 2019 [11] | 72, 72 | 27 | NA | NA | NA | 0 | 0 | 2 | 0 |
| Yap et al., 2020 [12] | 72 | 35 | NA | NA | 40 | 1 | 0 | 0 | 0 |
| Long and Mahoney, 2018 [13] | 50 | 50 | NA | 141 | 80 | 1 | 0 | 0 | 0 |
| Lotfi et al., 2017 [14] | 12 | Impaired with LVAD | EuroSCORE: 24.36% | NA | NA | 0 | 0 | 1 | 0 |
| Nascimento et al., 2019 [15] | NA | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Toggweiler et al., 2018 [16] | 96 | NA | NA | NA | 26 | 0 | 0 | 1 | 0 |
| Yamashita et al., 2019 [17] | 47 | NA | STS score: 9.5% | 95 | 58 | NA | NA | NA | NA |
| Salaun et al., 2019 [18] | 62.4 ± 23 (range 36–96) | NA | NA | NA | 39.6 ± 13.8 | 3 | 1 | 1 | 0 |
| Total | 58.1 ± 23.4 (21 cases) | 41 ± 10.2% | – | 84 ± 43.8 | 44.5 ± 18.5 | 61/159 (38.4%) | 47/159 (29.5%) | 50/159 (31.4%) | 14/159 (8.8%) |
LVAD: left ventricle assist device; LVEF: left ventricular ejection fraction; NA: data not available in the paper; TAVR: transcatheter aortic valve replacement; THV: transcatheter heart valve.
| Author, year . | Time since first TAVR (months) . | Mean LVEF (%) . | Risk scores . | Peak gradient of degenerated THV (mean) . | Mean gradient of degenerated THV (mean) . | Pure stenosis of degenerated THV (n) . | Mixed stenosis and regurgitation of degenerated THV (n) . | Pure regurgitation of degenerated THV (n) . | Thrombosis of previous THV (n) . |
|---|---|---|---|---|---|---|---|---|---|
| Landes et al., 2020 [6] | 60 (range 18–72) | 51.1 ± 12 | NA | 57.2 ± 31.4 | 34.7 ± 19.9 | 51 (37%) | 45 (32.6%) | 41 (29.7%) | 14 (10.2%) |
| Tsuda et al., 2019 [7] | 46 ± 15.9 (range 24–60) | 61 (range 38–70) | STS score (%): 8.6 (range 5.8–22.5) | 43 | 33.3 | 3 | 1 | 2 | 0 |
| Abdel-Wahab et al., 2020 [8] | 84 | NA | NA | NA | NA | 1 | 0 | 0 | 0 |
| Eftychiou et al., 2018 [9] | 84 | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Hoffmann et al., 2012 [10] | 42 | 42 | EuroSCORE: 32% | NA | 45 | 1 | 0 | 0 | 0 |
| Jędrzejczyk et al., 2019 [11] | 72, 72 | 27 | NA | NA | NA | 0 | 0 | 2 | 0 |
| Yap et al., 2020 [12] | 72 | 35 | NA | NA | 40 | 1 | 0 | 0 | 0 |
| Long and Mahoney, 2018 [13] | 50 | 50 | NA | 141 | 80 | 1 | 0 | 0 | 0 |
| Lotfi et al., 2017 [14] | 12 | Impaired with LVAD | EuroSCORE: 24.36% | NA | NA | 0 | 0 | 1 | 0 |
| Nascimento et al., 2019 [15] | NA | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Toggweiler et al., 2018 [16] | 96 | NA | NA | NA | 26 | 0 | 0 | 1 | 0 |
| Yamashita et al., 2019 [17] | 47 | NA | STS score: 9.5% | 95 | 58 | NA | NA | NA | NA |
| Salaun et al., 2019 [18] | 62.4 ± 23 (range 36–96) | NA | NA | NA | 39.6 ± 13.8 | 3 | 1 | 1 | 0 |
| Total | 58.1 ± 23.4 (21 cases) | 41 ± 10.2% | – | 84 ± 43.8 | 44.5 ± 18.5 | 61/159 (38.4%) | 47/159 (29.5%) | 50/159 (31.4%) | 14/159 (8.8%) |
| Author, year . | Time since first TAVR (months) . | Mean LVEF (%) . | Risk scores . | Peak gradient of degenerated THV (mean) . | Mean gradient of degenerated THV (mean) . | Pure stenosis of degenerated THV (n) . | Mixed stenosis and regurgitation of degenerated THV (n) . | Pure regurgitation of degenerated THV (n) . | Thrombosis of previous THV (n) . |
|---|---|---|---|---|---|---|---|---|---|
| Landes et al., 2020 [6] | 60 (range 18–72) | 51.1 ± 12 | NA | 57.2 ± 31.4 | 34.7 ± 19.9 | 51 (37%) | 45 (32.6%) | 41 (29.7%) | 14 (10.2%) |
| Tsuda et al., 2019 [7] | 46 ± 15.9 (range 24–60) | 61 (range 38–70) | STS score (%): 8.6 (range 5.8–22.5) | 43 | 33.3 | 3 | 1 | 2 | 0 |
| Abdel-Wahab et al., 2020 [8] | 84 | NA | NA | NA | NA | 1 | 0 | 0 | 0 |
| Eftychiou et al., 2018 [9] | 84 | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Hoffmann et al., 2012 [10] | 42 | 42 | EuroSCORE: 32% | NA | 45 | 1 | 0 | 0 | 0 |
| Jędrzejczyk et al., 2019 [11] | 72, 72 | 27 | NA | NA | NA | 0 | 0 | 2 | 0 |
| Yap et al., 2020 [12] | 72 | 35 | NA | NA | 40 | 1 | 0 | 0 | 0 |
| Long and Mahoney, 2018 [13] | 50 | 50 | NA | 141 | 80 | 1 | 0 | 0 | 0 |
| Lotfi et al., 2017 [14] | 12 | Impaired with LVAD | EuroSCORE: 24.36% | NA | NA | 0 | 0 | 1 | 0 |
| Nascimento et al., 2019 [15] | NA | Impaired | NA | NA | NA | 0 | 0 | 1 | 0 |
| Toggweiler et al., 2018 [16] | 96 | NA | NA | NA | 26 | 0 | 0 | 1 | 0 |
| Yamashita et al., 2019 [17] | 47 | NA | STS score: 9.5% | 95 | 58 | NA | NA | NA | NA |
| Salaun et al., 2019 [18] | 62.4 ± 23 (range 36–96) | NA | NA | NA | 39.6 ± 13.8 | 3 | 1 | 1 | 0 |
| Total | 58.1 ± 23.4 (21 cases) | 41 ± 10.2% | – | 84 ± 43.8 | 44.5 ± 18.5 | 61/159 (38.4%) | 47/159 (29.5%) | 50/159 (31.4%) | 14/159 (8.8%) |
LVAD: left ventricle assist device; LVEF: left ventricular ejection fraction; NA: data not available in the paper; TAVR: transcatheter aortic valve replacement; THV: transcatheter heart valve.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
